DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

when a CGM and insulin pump coordinate to deliver insulin when needed. The company is in partnership discussions with pump manufacturers, Ascensia President of CGM Brian Hansen said in a Tuesday ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom faces significant headwinds, including slower customer growth and increased competition. Learn more on DXCM here.

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

The device, called Lingo, will compete with a rival from DexCom (DXCM.O), opens new tab, launched last week, and will be available for adults who are not on insulin. Continuous glucose monitors ...

Abbott Laboratories launches its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.

Dexcom designs and commercializes continuous glucose monitoring ... and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin ...